Table 1 Relationship between intratumoral PCSK9 expression and clinicopathological features of HCC patients
From: PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma
Variable | PCSK9 expression | p | |
|---|---|---|---|
Low | High | ||
Age (years) | |||
 ≤ 50 | 23 | 14 | 0.851 |
 > 50 | 41 | 27 |  |
Gender | |||
 Female | 10 | 5 | 0.624 |
 Male | 54 | 36 |  |
AFP (ng/ml) | |||
 ≤ 20 | 25 | 19 | 0.461 |
 > 20 | 39 | 22 |  |
Number of tumors | |||
 Single | 44 | 28 | 0.961 |
 Multiple | 20 | 13 |  |
Tumor size (cm) | |||
 ≤ 5 | 43 | 14 | 0.001 |
 > 5 | 21 | 27 |  |
Tumor cell differentiation | |||
 I–II | 45 | 30 | 0.752 |
 III–IV | 19 | 11 |  |
Microvascular invasion | |||
 No | 32 | 12 | 0.036 |
 Yes | 32 | 29 |  |